Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a non-profit phase II, open-label, single-arm study of cetuximab plus avelumab in
patients with RAS WT mCRC treated in first line with chemotherapy in combination with an
anti- EGFR drug that have had a clinical benefit (complete or partial response) from
treatment.